T. Rowe Price Investment Management, Inc. Vaxcyte, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 6,001,124 shares of PCVX stock, worth $180 Million. This represents 0.12% of its overall portfolio holdings.
Number of Shares
6,001,124
Previous 2,702,691
122.04%
Holding current value
$180 Million
Previous $102 Million
91.17%
% of portfolio
0.12%
Previous 0.07%
Shares
11 transactions
Others Institutions Holding PCVX
# of Institutions
323Shares Held
139MCall Options Held
229KPut Options Held
160K-
Janus Henderson Group PLC London, X014.7MShares$441 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$360 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$359 Million8.5% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$298 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA4.95MShares$149 Million0.03% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $1.78B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...